HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape
Ritu Salani, MD, discusses impactful efficacy signals from T-DXd in the DESTINY-PanTumor02 study for endometrial cancer, marking a potential breakthrough in this treatment field.
EP: 1.Exploring HER2 as a Pan Tumor Biomarker
EP: 2.HER2 in Breast Cancer: Shaping Treatment in Other Solid Tumors
EP: 3.Expert Insights on HER2-Directed ADCs in Breast Cancer
EP: 4.Targeting HER2 Alterations with ADCs in NSCLC
EP: 5.Landscape Surrounding HER2 ADCs in GI Cancers
EP: 6.Emerging Data for HER2 ADCs in Ovarian Cancer
EP: 7.HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape
EP: 8.HER2 ADCs in Cervical Cancer: A Promising Therapeutic Frontier
EP: 9.Expert Insights on HER2 Testing in Gynecological Cancers
EP: 10.Future Perspectives on HER2 ADCs in Gynecological Cancer
Dr. Ritu Salani discusses the impact of the DESTINY-PanTumor02 trial on the treatment of endometrial cancer, highlighting the promising results and potential implications for clinical practice.
Prior to the DESTINY-PanTumor02 trial, a phase 2 trial investigated the combination of carboplatin, paclitaxel, and trastuzumab followed by trastuzumab maintenance in endometrial cancer. This trial, which used breast cancer IHC expression criteria, showed improved progression-free and overall survival compared to carboplatin and paclitaxel alone. A phase 3 trial was being developed to further explore this approach.
However, the DESTINY-PanTumor02 trial disrupted these plans in a positive way. The trial demonstrated an overall response rate of nearly 60% in all endometrial cancer patients and an impressive 85% response rate in those with IHC 3+ expression. These results were particularly remarkable considering that the trial focused on recurrent cancer.
At the 14-month follow-up, the median progression-free survival had not been reached in the IHC 3+ group, further emphasizing the significance of the findings. Endometrial cancer treatment has seen exciting developments, such as the use of immunotherapy in the front-line setting for mismatch repair-deficient groups, but the DESTINY-PanTumor02 results highlight the importance of HER2 expression, particularly HER2 3+ expression, in this cancer type.
The data from the DESTINY-PanTumor02 trial has already been incorporated into the NCCN guidelines, and there is hope for tumor-agnostic approval based on these results. Dr. Salani's enthusiasm underscores the potential impact of these findings on the management of endometrial cancer.
Summary generated by Claude AI.
